Incurin Tablets 1 mg
Control of Urinary Incontinence in Dogs
Merck Incurin Tablets are indicated for the control of estrogen-responsive urinary incontinence in ovariohysterectomized (spayed) female dogs. Hormone responsive incontinence is associated with a decrease in urine sphincter tone caused by the decrease in reproductive hormones. Urinary incontinence is most often seen in the older spayed female.
Incurin Tablets is alternative treatment for incontinence when phenylpropanolamine (PPA, Proin) is no longer affective or when Incurin is the first choice in therapy.
Dosage and Administration:
of INCURIN Tablets is not dependent upon body weight. All dogs should
receive an initial dose of 2 mg INCURIN Tablets (2 tablets) orally once
per day for a minimum of 14 days. After urinary incontinence is
controlled, the lowest effective daily dose of INCURIN Tablets should
be determined by decreasing the dose in a step-wise manner from 2 mg
once daily (2 tablets) to 1 mg once daily (1 tablet), then 0.5 mg once
daily (1/2 tablet) depending upon the response of the individual dog.
There should be a minimum of 7 days between each dose adjustment. After
the lowest daily dose that controls urinary incontinence is identified,
the dose may be decreased further by administering once every two days.
Dogs should not receive more than 2 mg INCURIN Tablets per day
(2 tablets). If the dog does not respond to 2 mg of INCURIN Tablets per
day, the diagnosis should be re-assessed.
Human Warnings: Not for human use.
Keep out of the reach of children. Women who are of child-bearing age or
those who are breastfeeding should use caution when administering
INCURIN Tablets. Wash your hands with soap and water after
administration to avoid exposure to the drug. Consult a physician in
case of accidental ingestion by humans.
Animal Warnings: Some estrogens have
been associated with bone marrow changes and an increased risk of
mammary tumors. However, target animal safety study results and foreign
post-market pharmacovigilance data for INCURIN™ Tablets have shown that
estriol-treated dogs are at low risk for developing these conditions.
Precautions: Evaluation of factors contributing to urinary incontinence should be considered prior of administration of INCURIN Tablets.
Do not use with other estrogens. The concomitant use of INCURIN™ Tablets with other estrogens has not been evaluated.
The concomitant use of INCURIN Tablets with glucocorticoids has not been evaluated.
The use of INCURIN Tablets in dogs with liver disease has not been evaluated.
The safe use of INCURIN Tablets has not been evaluated
in intact female dogs, pregnant or lactating dogs, male dogs, and dogs
less than 1 year of age.
Federal law restricts this drug to use by or on the order of a licensed veterinarian
Packaging: Incurin (Estriol) 1 mg, 30 Dose Blister Pack
Merck Animal Health